evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

12 questions · 12 findings · 4 reviews · Epilepsy

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 16.7%Low 5 · 41.7%Moderate 5 · 41.7%High 0 · 0%

Perampanel add‐on vs placebo

Withdrawals due to adverse events · people (aged 12 years and over) with drug‐resistant focal epilepsy

Perampanel add‐on may leads to higher treatment withdrawal due to adverse effects compared with placebo (low certainty).

1 finding from 1 review

Pregabalin vs placebo

Withdrawals due to adverse events · people with drug‐resistant focal epilepsy

Pregabalin probably leads to higher treatment withdrawal due to adverse effects compared with placebo (moderate certainty).

1 finding from 1 review

Zonisamide vs placebo

Nausea · people with focal epilepsy

Zonisamide probably leads to higher adverse effects: nausea (whole treatment period; any dose) compared with placebo (moderate certainty).

1 finding from 1 review

Zonisamide vs placebo

Adverse effect: fatigue · people with focal epilepsy

Zonisamide probably leads to higher adverse effects: fatigue (whole treatment period; any dose) compared with placebo (moderate certainty).

1 finding from 1 review

Zonisamide vs placebo

Frequency of adverse effects ‐ dizziness ( · people with focal epilepsy

Zonisamide probably leads to higher adverse effects: dizziness (whole treatment period; any dose) compared with placebo (moderate certainty).

1 finding from 1 review

Zonisamide vs placebo

Somnolence · people with focal epilepsy

Zonisamide probably leads to higher adverse effects: somnolence (whole treatment period; any dose) compared with placebo (moderate certainty).

1 finding from 1 review

Vigabatrin vs placebo

Ataxia · people (aged 10–64 years) with drug‐resistant focal epilepsy

It is very uncertain whether vigabatrin changes adverse effects: ataxia Duration of treatment (range): 7–36 weeks compared with placebo (very low certainty).

1 finding from 1 review

Vigabatrin vs placebo

Adverse effect: fatigue · people (aged 10–64 years) with drug‐resistant focal epilepsy

Vigabatrin may leads to higher adverse effects: fatigue Duration of treatment (range): 8–36 weeks compared with placebo (low certainty).

1 finding from 1 review

Vigabatrin vs placebo

Adverse effects: nystagmus Duration of treatment (range): 16–18 weeks · people (aged 10–64 years) with drug‐resistant focal epilepsy

Vigabatrin showed no clear difference in adverse effects: nystagmus Duration of treatment (range): 16–18 weeks compared with placebo (low certainty).

1 finding from 1 review

Vigabatrin vs placebo

Adverse effects: abnormal vision Duration of treatment (range): 8–36 weeks · people (aged 10–64 years) with drug‐resistant focal epilepsy

It is very uncertain whether vigabatrin changes adverse effects: abnormal vision Duration of treatment (range): 8–36… compared with placebo (very low certainty).

1 finding from 1 review

Vigabatrin vs placebo

Adverse effects: dizziness, lightheadedness · people (aged 10–64 years) with drug‐resistant focal epilepsy

Vigabatrin may leads to higher adverse effects: dizziness/light‐headedness Duration of treatment… compared with placebo (low certainty).

1 finding from 1 review